TRI Dental Implants Int. AG (“TRI®”) announces that Geistlich Pharma AG has acquired a minority stake in the company.

At the heart of TRI®’s innovation is the matrix®, the world’s first dental implant system without an abutment. By eliminating abutments and enabling prosthetic crowns to be screwed directly onto the implant, TRI® simplifies the implant workflow, saving significant time and cost. Combined with a suite of 10 digital apps, the system empowers clinicians with seamless, fully digital solutions for patient care.

Geistlich and TRI® share a foundation of Swiss quality, innovation, and scientific excellence. While TRI® continues its independent, founder-led path and international expansion, the investment underscores a shared vision in digital technologies to shape a patient-centered future in dentistry.